Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Cancer Therapies

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

Inhibition of Cdk Activity

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Correction to: Lenacapavir: First Approval.

Drugs·2023

Same author

Lenacapavir: First Approval.

Drugs·2022

Same author

Correction to: Ozanimod: A Review in Ulcerative Colitis.

Drugs·2022

Same author

Ozanimod: A Review in Ulcerative Colitis.

Drugs·2022

Same author

Dabigatran Etexilate: A Review in Pediatric Venous Thromboembolism.

Paediatric drugs·2022

Same author

Nivolumab Plus Relatlimab: First Approval.

Drugs·2022

Search research articles

Related Experiment Video

Updated: Oct 17, 2025

Visualizing DNA Damage Repair Proteins in Patient-Derived Ovarian Cancer Organoids via Immunofluorescence Assays

Visualizing DNA Damage Repair Proteins in Patient-Derived Ovarian Cancer Organoids via Immunofluorescence Assays

Published on: February 24, 2023

Olaparib: A Review as First-Line Maintenance Therapy in Advanced Ovarian Cancer.

¹Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. demail@springer.com.

Targeted Oncology

|October 8, 2021

Summary

Olaparib, a PARP inhibitor, is effective for first-line maintenance in advanced ovarian cancer. It significantly improves progression-free survival in patients with HRD-positive tumors when used alone or with bevacizumab.

More Related Videos

Evaluating In Vitro DNA Damage Using Comet Assay

Evaluating In Vitro DNA Damage Using Comet Assay

Published on: October 11, 2017

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Related Experiment Videos

Last Updated: Oct 17, 2025

Visualizing DNA Damage Repair Proteins in Patient-Derived Ovarian Cancer Organoids via Immunofluorescence Assays

Visualizing DNA Damage Repair Proteins in Patient-Derived Ovarian Cancer Organoids via Immunofluorescence Assays

Published on: February 24, 2023

Evaluating In Vitro DNA Damage Using Comet Assay

Evaluating In Vitro DNA Damage Using Comet Assay

Published on: October 11, 2017

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Area of Science:

Oncology
Pharmacology

Background:

Olaparib is a PARP inhibitor used for advanced ovarian cancer maintenance therapy.
It is approved as monotherapy and in combination with bevacizumab for HRD-positive cancers.

Purpose of the Study:

To evaluate the efficacy of olaparib monotherapy and olaparib plus bevacizumab in first-line maintenance treatment for advanced ovarian cancer.
To assess outcomes based on homologous recombination deficiency (HRD) status.

Main Methods:

Phase III trials (SOLO-1 and PAOLA-1) were conducted.
Patients with advanced ovarian cancer responding to platinum-based chemotherapy were included.
Progression-free survival (PFS) was a primary endpoint.

Main Results:

Olaparib monotherapy significantly improved PFS versus placebo (SOLO-1).
Olaparib plus bevacizumab significantly improved PFS versus placebo plus bevacizumab (PAOLA-1).
Improvements in PAOLA-1 were not observed in HRD-negative tumors.

Conclusions:

Olaparib, alone or with bevacizumab, is a valuable first-line maintenance option for HRD-positive advanced ovarian, fallopian tube, or primary peritoneal cancer.
Treatment efficacy is dependent on HRD status, particularly for the combination therapy.